The retatrutide grey market: what is actually being sold, and what to check

Photograph: editorial illustration for this article. It does not show retatrutide.

Why is there a retatrutide grey market?

The gap between evidence and availability. Retatrutide's phase 3 results are public: −28.3% mean weight change at 80 weeks on 12 mg in TRIUMPH-1, announced by Lilly on 21 May 2026^[2]. Its approval is not: Lilly plans to file with the FDA in the first quarter of 2027^[1], and a decision would follow months after that. A drug that has demonstrated an effect this large, from a well-known company, with no legal way to obtain it, produces demand that someone will meet. Searches for retatrutide grey market are modest, 260 a month in the United States, but searches for where to obtain it run into the thousands, according to Google Ads data we pulled in September 2026.

The molecule is also synthesisable. It is a 39-amino-acid peptide with a lipid chain^[5], well within the capability of contract peptide manufacturers, and its sequence has been public since 2022. That is why supply exists at all.

What are the three channels?

Research-use-only suppliers

These companies sell synthetic peptides to laboratories, labelled for research use only and not for human consumption. The better ones publish a certificate of analysis for each lot, name the testing laboratory, state where they ship from, and refuse to discuss dosing. This is the channel through which the compound legitimately exists outside Lilly. It is not a pharmacy, and its product is not a medicine.

Sellers presenting it as a compounded medicine

Some telehealth-style sellers describe retatrutide as available "compounded". In the United States this has no legal basis, because compounding pharmacies may only work from approved drugs or from bulk substances on FDA lists, and retatrutide is neither. A product described this way is an unapproved drug with a medical-sounding label.

Social-media resellers

Individuals and small operations reselling through messaging apps and forums, typically with no certificate of analysis, no lot numbers and no traceable origin. This is where most of the risk sits: the product may be under-dosed, degraded, a different peptide, or nothing at all, and there is no document to check.

What is the legal status in the United States?

Three rules cover it. A substance intended to affect the structure or function of the body is a drug under the Federal Food, Drug, and Cosmetic Act, and a drug without an approved application is an unapproved new drug that cannot be lawfully marketed for human use. Selling a peptide for laboratory research, labelled as such, is a different act and is permitted. And compounding, under sections 503A and 503B of the same Act, is restricted to approved drugs and listed bulk substances. Retatrutide therefore has one lawful commercial existence in the United States today, as a research reagent, and one lawful human route, a clinical trial or FDA expanded access. That is the whole legal map, and it will stay this way until an application is approved.

What is the legal status in Europe?

Similar in structure. Medicinal products need a marketing authorisation from the European Medicines Agency (https://www.ema.europa.eu) or a national agency before they can be supplied to patients; retatrutide has none and no European application has been announced. Research chemicals can be sold to laboratories under chemical rather than pharmaceutical law. The United Kingdom, Switzerland and the EU member states each apply their own import rules to personal shipments, and customs seizure of unapproved peptides is common.

What can a buyer actually verify?

• The certificate of analysis for the exact lot, with identity by mass spectrometry, purity by HPLC and, ideally, net content. The sections are explained in how to read a retatrutide COA.
• The laboratory that issued it, which should be findable and willing to confirm the report number.
• The origin of shipment, because it determines customs exposure and how long a lyophilised peptide has spent in transit.
• The supplier's own wording. A supplier that says research use only and means it does not discuss protocols; one that offers dosing advice is marketing a drug.

What cannot be verified: reviews, before-and-after photographs, forum reputation and the claim that a product "is the same as the trial drug". The trial drug was manufactured under pharmaceutical GMP for 338 people in phase 2^[3] and 2,335 in TRIUMPH-1^[4]; no research supplier makes that material.

The only legal route to human use

Clinical trials, and in the United States a pre-approval expanded access program that Lilly has registered on ClinicalTrials.gov. TRIUMPH-Outcomes is no longer recruiting, but other retatrutide studies open and close, and the registry is the place to look. What the completed trials found, dose by dose, is on our clinical trials page, and the approval timeline is tracked in retatrutide FDA approval.